Osteoporosis class Chinese medicine sales growth rebounded in Beijing

Business Club May 31st News Osteoporosis is an age-related illness. The higher the age of the population, the more patients suffer. China is the country with the largest number of elderly people. There are about 90 million osteoporosis patients, accounting for 7.1% of the total population. With the advancement of aging society, the incidence of osteoporosis is on the rise and it is expected to increase to 221 million by 2050. At that time, more than half of osteoporotic fractures in the world will occur in Asia. Part in our country. This data has to draw the attention of the people.

The understanding of osteoporosis in Western medicine has been nearly 180 years since its naming. Although there is no such name in traditional Chinese medicine, there have been similar prescriptions for clinical description and treatment for thousands of years. Chinese medicine classified osteoporosis into the category of "bone sputum, bone sputum, and bone sputum" and considered its pathogenesis as kidney deficiency and spleen deficiency. Therefore, the treatment of kidney and spleen, and Qi and spleen are recommended for the pathogenesis. In addition to delaying the development of the disease, TCM treatment can be distinguished and treated from the disease itself, so that treating both the symptoms and the disease has special significance.

Increased dosage of Chinese medicine in hospital terminal

According to the data of the "Pharmaceutical Surveillance and Analysis System for Chinese Medicine and Western Medicine Hospital of China (hereinafter referred to as "HDM System") by SFDA Southern Medical Economic Research Institute Guangzhou Puncak Medical Information Co., Ltd., in Beijing, Chengdu, Guangzhou, Harbin, Nanjing, Shenyang, Xi'an, Zhengzhou In the 9 cities of Chongqing (hereinafter referred to as 9 major cities), the procurement scale of osteoporosis Chinese patent medicines has been increasing year by year from 2007 to 2010 (see Figure 1). The average annual growth rate is 27%, which is higher than that of 9 major urban hospitals. The terminal's procurement of all Chinese patent medicines had an average growth rate (22%) and was in a period of rapid growth.

In particular, in October 2008, the International Osteoporosis Foundation and the China Health Promotion Foundation jointly released the White Paper on Prevention and Treatment of Osteoporosis, raising the public’s awareness of the dangers of osteoporosis and the government’s commitment to osteoporosis. Reimbursement incentives for proprietary Chinese medicines, such as the inclusion of Xianlingguyu capsules (chips) and Gushukang capsules (granules) in the national health insurance catalog in 2008, all of which are related to osteoporosis in 2008. The rapid growth of sales of proprietary Chinese medicines contributed.

Compared with the strong growth trend in 2008, the growth rate of Chinese patent medicines for osteoporosis in 2009 did not appear to be “forced” and slightly fatigued. However, due to the acceleration of the aging process in China, the elderly population has grown rapidly, and the national economy of our country has also been growing rapidly. This has made it possible for people to impose higher requirements on the quality of life. This will inevitably lead to the demand for osteoporosis drugs. increase. From the rebound of the sales growth rate of osteoporosis Chinese patent medicines in 2010, the osteoporosis proprietary Chinese medicine market will continue to expand, and the market potential cannot be ignored.

Beijing procurement lead

It can be seen from Figure 2 that the purchase amount of osteoporosis proprietary Chinese medicines in hospitals in the nine major cities is increasing.

From the perspective of purchasing scale, the largest is Beijing, which is related to the education of patients. The data show that Beijing is the first city to promote the harm of osteoporosis, which makes more patients concerned about osteoporosis and seek medical attention. Furthermore, the current osteoporosis diagnosis and treatment facilities in Beijing are more advanced than those in other cities in the country. Early patients are more likely to be diagnosed and treated earlier.

However, from the point of view of purchase growth rate, the fastest-growing is Shenyang, with an average annual growth rate of 106%. This may be related to the late entry of osteoporosis Chinese patent medicines into this market and relatively sufficient stamina. It is expected that it will maintain this good momentum this year.

Chinese medicine brand tripartite tripartite

The development of osteoporosis proprietary Chinese medicines can be traced back to 1994 when the country first approved Xianlingguyu capsule as its indication medicine. After 17 years of development, the number of osteoporosis Chinese patent medicines is still very small. HDM system data shows that 9 major cities and hospitals have purchased more than 10 varieties of terminal equipment. In addition to the kidney capsule, there are 4 manufacturers and all other products are exclusive products.

In 2010, the total market share (CR3) of the top 3 products in the terminal osteoporosis market of hospitals in 9 cities reached 75%, and the market concentration was extremely high. Among them, Shanxi Jinhua Enterprise (Group) Co., Ltd.'s Jintiange Capsules topped the list with a 35% market share; followed by Tongjitang Pharmaceutical Co., Ltd. of Guizhou Xianlingguyu Capsules, with a market share of 21%; followed by This was followed by a strong bone capsule produced by Beijing Haohuang Pharmaceutical Co., Ltd., which has a 19% market share.

It is noteworthy that Jintiange capsules have grown rapidly, and the compound growth rate reached 131% during the four years from 2007 to 2010. Jintiange capsule was formally put on the market in 2005, has passed the market incubation period, entered a period of rapid growth, can be seen from Figure 3, after its market share began in 2009 beyond Xianlingguyu capsule, in the osteoporosis class of proprietary Chinese medicine The market has always been a leader.

The main active ingredient of Jintiange capsule is artificial tiger bone powder. The use of artificial tiger bone powder to replace the traditional tiger bone has a significant effect. It has obvious effects on improving the bone mineral density, relieving low back pain, weak knees, and sore leg. This is another major breakthrough in the development of wild animal artificial substitutes after the successful development of artificial musk. Therefore, in June 2003, artificial tiger bone meal and Jintiange capsule obtained “national invention patent”. The patent protection period is 20 years, and the artificial tiger bone meal prescription and technology are recognized as national top secret. At the same time, Jintiange capsules have also been included in the 2009 edition of the National Health Insurance Catalogue Category B Drug List as a new class of drugs. For Jintiange capsules with dual trump cards, the road ahead will be brighter.

For Xianlingguyu Capsules, which had a market share of 21% in 2010, sales volume has been increasing during the four years. However, in the face of the strong offensive of Jintiange capsules, market share is shrinking year by year. At the same time, it is also affected by strong bone capsules that also entered the medical insurance catalog, and the market prospects are worrying. As the medical reforms are not yet clear, it is also a test for the Xianlinggufen capsules to enter the base medicine list. However, comparing the 2004 version of the National Health Insurance Catalogue, the 2009 edition of the National Medical Insurance Catalog has upgraded the Xianlingguyu capsule from Medicare B to A, which shows that it is still recognized by the state.

2L-size Carrot

2L-size Carrot,2L-size Fresh Carrot,Fresh Carrot Size 2L,2L-size Red Color Carrot

Yirun Agricultural Cooperative , https://www.yiruncn.com

Posted on